Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00017056
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT00077376
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
- Conditions
- Distal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the Bladder
- Interventions
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00021099
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00070096
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
BMS-247550 in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-09-10
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00020904
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
- Conditions
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00017043
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-06
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 2
- Registration Number
- NCT00033306
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Georgia Cancer Specialists, Atlanta, Georgia, United States
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00058084
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00057850
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00058019
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.